PubRank

Hinrich Abken

Author PubWeight™ 65.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007 2.50
2 T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 2013 1.77
3 IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 2011 1.33
4 T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004 1.33
5 CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 2012 1.32
6 Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A 2011 1.31
7 Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A 2009 1.23
8 Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A 2008 1.18
9 HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 2003 1.17
10 Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget 2012 1.11
11 Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 2010 1.10
12 The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008 1.09
13 Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One 2012 1.08
14 Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res 2011 1.07
15 Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007 1.07
16 Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Mol Ther 2013 1.05
17 Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther 2010 1.04
18 CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res 2007 1.04
19 Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther 2010 1.03
20 T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012 1.03
21 Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2. J Immunol 2007 1.02
22 OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012 1.01
23 Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer 2011 1.01
24 CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther 2011 1.00
25 Depletion of annexin A5, annexin A6, and collagen X causes no gross changes in matrix vesicle-mediated mineralization, but lack of collagen X affects hematopoiesis and the Th1/Th2 response. J Bone Miner Res 2012 0.99
26 The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res 2010 0.99
27 T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 2007 0.98
28 Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol 2013 0.98
29 Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J Immunol 2006 0.97
30 XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood 2006 0.97
31 Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012 0.95
32 T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 2007 0.95
33 Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 2012 0.94
34 Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 2014 0.92
35 Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol 2012 0.92
36 Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol 2011 0.91
37 CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother 2012 0.90
38 Conditions of retinal glial and inflammatory cell activation after irradiation in a GFP-chimeric mouse model. Invest Ophthalmol Vis Sci 2010 0.90
39 Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum Gene Ther 2013 0.89
40 A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother 2014 0.87
41 The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells. PLoS One 2012 0.87
42 Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis. Int J Cancer 2005 0.87
43 An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack. PLoS One 2012 0.86
44 The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget 2011 0.85
45 Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. Cancer Res 2003 0.85
46 TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 2015 0.85
47 Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. Methods Mol Biol 2013 0.84
48 Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing. Leuk Lymphoma 2013 0.84
49 T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol 2010 0.83
50 Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy. Cancer Immunol Immunother 2006 0.83
51 Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Immunotherapy 2013 0.82
52 CD7(-) T cells are late memory cells generated from CD7(+) T cells. Rejuvenation Res 2008 0.82
53 Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells. Am J Pathol 2013 0.82
54 Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells. Int J Cancer 2003 0.82
55 B7/CD28 costimulation of T cells induces a distinct proteome pattern. Mol Cell Proteomics 2005 0.82
56 Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology 2003 0.81
57 Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle. Front Immunol 2013 0.81
58 Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells. Int J Cancer 2004 0.80
59 Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy. Methods Mol Biol 2003 0.80
60 A proteomic view at T cell costimulation. PLoS One 2012 0.80
61 Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol 2011 0.79
62 Extensive amplification of human regulatory T cells alters their functional capacities and targets them to the periphery. Rejuvenation Res 2008 0.77
63 The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr Gene Ther 2002 0.77
64 Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma. Expert Rev Hematol 2015 0.77
65 B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy. Int J Cancer 2005 0.76
66 Targeting two co-operating cytokines efficiently shapes immune responses. Oncoimmunology 2013 0.76
67 CAR's made it to the pancreas. Oncoimmunology 2012 0.75
68 PECAM1(+)/Sca1(+)/CD38(+) vascular cells transform into myofibroblast-like cells in skin wound repair. PLoS One 2013 0.75
69 Antibody-IL2 fusion proteins for tumor targeting. Methods Mol Biol 2012 0.75